By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Altria, with concerns about slowing nicotine pouch growth, competition, and the risk of FDA delays. The 7.3% EPS growth and on! pouch momentum are not enough to offset structural cigarette decline and the need for a successful pivot to smoke-free products.
Risk: The capital allocation trap, where Altria's high dividend yield crowds out R&D and M&A needed to pivot away from combustibles, is the single biggest risk flagged by the panel.
Opportunity: No significant opportunities were highlighted by the panel.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Altria Group, Inc. (NYSE:MO) is included among the 10 Best Long Term Low Risk Stocks to Buy According to Hedge Funds.
On May 15, Barclays raised its price recommendation on Altria Group, Inc. (NYSE:MO) to $64 from $63. It reiterated an Underweight rating on the stock. The firm said the latest FDA guidance could lead to more innovation across the tobacco sector. Barclays believes that could accelerate growth in next-generation products and potentially drive a re-rating of tobacco stocks.
During the Q1 2026 earnings call, CEO William Gifford described the quarter as a strong start to the year. He said adjusted diluted EPS increased 7.3% and noted that Altria’s highly cash-generative businesses continued supporting significant shareholder returns through dividends and share repurchases.
Speaking about oral nicotine pouches, Gifford pointed to continued category growth and the wider rollout of on! PLUS. He said reported shipment volume for the overall on! portfolio climbed nearly 18% to more than 46 million cans. He also noted that on! and on! PLUS together represented 7.8% of the total oral tobacco category. That figure was down 0.8 percentage points from the prior year but improved 0.2 percentage points sequentially.
Gifford added that on! PLUS started shipping nationwide in March and, by the end of the quarter, was available in roughly 100,000 stores. According to him, that represented 85% of the nicotine pouch category volume.
Altria Group, Inc. (NYSE:MO) operates a portfolio of tobacco products for U.S. tobacco consumers aged 21 and older. Its business is organized into smokeable products and oral tobacco products. The smokeable products segment includes combustible cigarettes and machine-made large cigars.
While we acknowledge the potential of MO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best Dividend Penny Stocks to Buy Right Now and 11 Best Long Term US Stocks to Buy Right Now
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Barclays' Underweight rating despite the small target raise shows skepticism that oral nicotine growth can drive meaningful re-rating for Altria."
Barclays' modest $1 price target hike to $64 on Altria while retaining Underweight status undercuts the re-rating narrative. Oral pouch shipments rose 18% to 46 million cans with on! PLUS reaching 100,000 stores, yet category share slipped 0.8 points year-over-year to 7.8%. Core combustible volumes remain under pressure, and any FDA-driven innovation faces lengthy approval timelines plus competition from larger reduced-risk portfolios. The 7.3% EPS growth cited is cash-generative but does little to offset structural cigarette decline. Focus should stay on whether sequential share gains in nicotine pouches can scale enough to move the needle on valuation multiples.
If FDA guidance materially shortens approval cycles for next-generation products, Altria could see faster margin expansion and multiple expansion than the Underweight rating anticipates.
"MO's market share in its fastest-growing segment is *shrinking* despite absolute volume growth, suggesting competitive pressure that a $1 price target raise and vague FDA optimism cannot offset."
Barclays raised MO to $64 while keeping Underweight—a contradiction that signals skepticism despite the price bump. The real story: on! PLUS gained 100k doors in one quarter, but MO's share of oral nicotine pouches *fell* 80bps YoY to 7.8%, meaning competitors are growing faster. Q1 EPS growth of 7.3% is solid but modest for a 're-rating' narrative. The FDA guidance angle is vague—what specific policy change justifies sector re-rating? The article conflates innovation potential with execution certainty. Dividend yield (~8%) is attractive but reflects market skepticism about long-term growth, not confidence.
If oral nicotine pouches become the dominant category and MO's on! PLUS achieves 15%+ market share by 2027 (plausible given 85% distribution reach), the stock could re-rate from 6x to 8x EBITDA, justifying $70+. The article undersells how quickly this category is shifting consumer behavior away from combustibles.
"Altria’s valuation re-rating is contingent on smoke-free products achieving scale that meaningfully offsets the structural, long-term decay of the combustible cigarette business."
Barclays’ price target hike to $64 while maintaining an 'Underweight' rating is a classic Wall Street hedge. It acknowledges the potential for a sector-wide valuation re-rating driven by FDA-approved innovation, yet remains deeply skeptical of Altria’s core combustible business. While the 7.3% EPS growth and 18% volume jump in 'on!' pouches are positive, they mask the structural decline of cigarette volumes, which remain the primary cash engine. At a forward P/E of roughly 9x, Altria is priced for terminal decline, not growth. A re-rating requires more than just 'on!' success; it requires a successful pivot to a smoke-free portfolio that can actually offset the inevitable contraction of the combustible segment.
The strongest bear case is that Altria’s 'on!' portfolio is losing market share to ZYN (PM), and the regulatory risk of a menthol ban or nicotine caps remains a persistent, unpriced existential threat.
"Regulatory risk and execution challenges in on! and other next-gen products could prevent MO from delivering the growth needed to justify a meaningful re-rating."
Barclays nudges Altria to $64 and calls for a sector re-rating on FDA guidance, but the fundamentals remain a mixed bag. Q1 2026 showed EPS up 7.3% and strong operating cash flow, with on! nicotine pouch momentum; the stock price gets a modest bump from a cautious 'Underweight' call. Yet the thrust depends on regulatory tailwinds materializing into durable growth for next-gen products, and the on! rollouts still face execution, discounting, and channel risks. The obvious bull case hinges on faster adoption of oral nicotine and favorable policy; the risk is that tighter FDA actions or weaker consumer demand could crush the re-rating thesis and keep multiples compressed.
However, the strongest counter-argument is that regulatory tailwinds may not materialize quickly, and any stumble in on! rollout or tighter nicotine rules could cap upside, leaving MO's modest target vulnerable.
"Ongoing share losses will force discounting that erodes margins faster than regulatory tailwinds can offset."
Gemini flags the hedge in Barclays' Underweight call but underplays how on!'s 18% volume lift collides with ongoing 0.8-point share erosion. Sustaining that growth against ZYN likely demands deeper discounting, which would squeeze the combustible margins funding the 7.3% EPS rise. If cash generation slows before FDA changes arrive, the 9x forward P/E already prices in that risk and leaves little room for multiple expansion.
"On! volume growth is real but mathematically immaterial to group earnings until it hits 20%+ category share, which requires years MO may not have."
Grok's discounting pressure argument is sound, but it assumes ZYN's cost structure mirrors MO's. ZYN (PM subsidiary) operates at lower margins than combustibles—they can undercut without destroying profitability the way Grok implies. The real risk isn't margin squeeze on on!; it's that on! never reaches scale fast enough to matter before combustible volumes crater. 18% growth on a 7.8% share base is still small dollars.
"Altria's dividend commitment creates a capital allocation trap that prevents the necessary investment to pivot away from declining combustible revenues."
Claude, you hit the critical point: the 'on!' growth rate is a vanity metric when the absolute share is stagnating. The real risk everyone is dancing around is the capital allocation trap. Altria is forced to defend its 8% yield to keep the share price from collapsing, which starves the necessary R&D and M&A required to pivot away from combustibles. They are essentially cannibalizing their future to fund a shrinking past, making the 9x P/E a value trap.
"MO's 8% yield may cap upside if on! growth stalls or regulatory delays prevent a meaningful pivot, making the stock a yield trap rather than a re-rating catalyst."
Gemini's hit on the 'capital allocation trap' rings true, but the risk is understated: MO's yield is not a free option — it funds the moat and may crowd out the R&D and M&A needed to actually tilt the mix toward non-combustibles. If on! growth stalls and regulators delay, the 8% yield becomes a brake on value rather than a catalyst for multiple expansion. The market may be pricing a pivot that hinges on timing.
The panel consensus is bearish on Altria, with concerns about slowing nicotine pouch growth, competition, and the risk of FDA delays. The 7.3% EPS growth and on! pouch momentum are not enough to offset structural cigarette decline and the need for a successful pivot to smoke-free products.
No significant opportunities were highlighted by the panel.
The capital allocation trap, where Altria's high dividend yield crowds out R&D and M&A needed to pivot away from combustibles, is the single biggest risk flagged by the panel.